CEO: Jeffrey M. Jonas

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Key numbers

Market Capitalization:2392891402
Shares Outstanding: 51917800
Float: 50907999
Next Earning Date:2020-08-10
TTm EPS: -12.4576
TTm Dividend Rate:
200 days moving average:66.95
50 days moving average: 40.78
One day percent Change: -0.83

2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,